Fast Five Quiz: COVID-19 Prevention

Michael Stuart Bronze, MD


December 16, 2022

As of data published in October 2022, the BA.4/5 bivalent Omicron-containing vaccine mRNA-1273.214 (Moderna) induced better neutralizing antibody responses against Omicron than the original ancestral mRNA-1273 vaccine. The bivalent booster also elicited higher binding antibody responses against Alpha, Beta, Gamma, and Delta. In addition, the bivalent vaccine that targets the original virus and the Omicron variant has proven superior to the original booster regardless of age and previous SARS-CoV-2 infection status.

In the EU, there are now multiple bivalent Omicron-containing vaccines available that target the original strain plus either Omicron BA.1 or Omicron BA.4-5 for people aged ≥ 12 years who have received at least primary vaccination against COVID-19.

Learn more about COVID-19 vaccines.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.